Longeveron Q2 net loss widens 22% to $6.07 million; revenue falls 10% to $287,000

Longeveron posted a net loss of $6.07 million, widening 22% year over year.

Revenue dipped 10% to $287,000, driven by no contract manufacturing revenue.

Operating loss widened to $6.17 million as operating expenses climbed 15% to $6.35 million.

Research and development spending rose 7% to $3.19 million on higher ELPIS II clinical trial costs.

Cash and cash equivalents totaled $10.1 million at June 30, 2026; cash runway is expected into Q4 2026.